Ponatinib-associated panniculitis: Case report and review of the literature

Abstract

Ponatinib is a tyrosine kinase inhibitor (TKI) approved for the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphoblastic leukemia. Common adverse effects of ponatinib include neutropenia, arterial thrombosis, and hypertension. We describe a 49-year-old woman who developed panniculitis after brief treatment with ponatinib. In addition, we summarize other studies describing TKI-associated panniculitis.

Keywords: ALL; Adverse drug reactions; CML; Panniculitis ponatinib; Tyrosine kinase inhibitors.